Pharma Mar Sa Stock Fundamentals
| PHM Stock | EUR 75.50 0.10 0.13% |
Pharma Mar SA fundamentals help investors to digest information that contributes to Pharma Mar's financial success or failures. It also enables traders to predict the movement of Pharma Stock. The fundamental analysis module provides a way to measure Pharma Mar's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharma Mar stock.
Pharma |
Pharma Mar SA Company Return On Equity Analysis
Pharma Mar's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Pharma Mar Return On Equity | 0.47 |
Most of Pharma Mar's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharma Mar SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Pharma Mar SA has a Return On Equity of 0.4705. This is 101.96% lower than that of the Healthcare sector and 101.29% lower than that of the Biotechnology industry. The return on equity for all Spain stocks is notably lower than that of the firm.
Pharma Mar SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pharma Mar's current stock value. Our valuation model uses many indicators to compare Pharma Mar value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pharma Mar competition to find correlations between indicators driving Pharma Mar's intrinsic value. More Info.Pharma Mar SA is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.28 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Pharma Mar SA is roughly 3.55 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Pharma Mar by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Pharma Mar's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Pharma Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharma Mar's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pharma Mar could also be used in its relative valuation, which is a method of valuing Pharma Mar by comparing valuation metrics of similar companies.Pharma Mar is currently under evaluation in return on equity category among its peers.
Pharma Fundamentals
| Return On Equity | 0.47 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.35 % | |||
| Operating Margin | 0.33 % | |||
| Current Valuation | 1.07 B | |||
| Shares Outstanding | 18.09 M | |||
| Shares Owned By Insiders | 26.95 % | |||
| Shares Owned By Institutions | 10.48 % | |||
| Price To Earning | (38.29) X | |||
| Price To Book | 5.69 X | |||
| Price To Sales | 5.17 X | |||
| Revenue | 229.83 M | |||
| Gross Profit | 213.39 M | |||
| EBITDA | 104.08 M | |||
| Net Income | 92.86 M | |||
| Cash And Equivalents | 42.72 M | |||
| Cash Per Share | 0.19 X | |||
| Total Debt | 33.39 M | |||
| Current Ratio | 0.94 X | |||
| Book Value Per Share | 9.88 X | |||
| Cash Flow From Operations | 25.68 M | |||
| Earnings Per Share | 4.64 X | |||
| Target Price | 76.34 | |||
| Number Of Employees | 477 | |||
| Beta | 0.12 | |||
| Market Capitalization | 1.09 B | |||
| Total Asset | 368.39 M | |||
| Z Score | 19.2 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 368.39 M | |||
| Last Dividend Paid | 0.65 |
About Pharma Mar Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharma Mar SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharma Mar using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharma Mar SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Pharma Mar, S.A., a biopharmaceutical company, engages in the discovery and development of marine-derived anticancer drugs in Spain and internationally. Pharma Mar, S.A. was founded in 1986 and is based in Madrid, Spain. PHARMA MAR operates under Biotechnology classification in Spain and is traded on Madrid SE C.A.T.S.. It employs 599 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Pharma Stock
Pharma Mar financial ratios help investors to determine whether Pharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharma with respect to the benefits of owning Pharma Mar security.